Status: Recruiting
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 and adibelizumab in the treatment of advanced malignant tumors, and to provide the recommended dose (RP2D) for subsequent clinical studies.
Participants needed: 203
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.Updated: Jan 22, 2026Locations: 1
Eligibility criteria
Voluntarily participate in this clinical study, understand the research procedur... [+5]
Symptomatic or active central nervous system (CNS) tumor metastasis; [+20]